Breaking News
Home / News / Lubiprostone to Lead the Global Irritable Bowel Syndrome with Constipation Market at a CAGR of 6.8% during 2016-2022

Lubiprostone to Lead the Global Irritable Bowel Syndrome with Constipation Market at a CAGR of 6.8% during 2016-2022

The latest market report published by Credence Research, Inc. “Global Irritable Bowel Syndrome with Constipation (IBS-C) Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016-2022,” the irritable bowel syndrome with constipation (IBS-C) drugs market was valued at USD 1,045 Mn in 2015, and is expected to reach USD 1,597.5 Mn by 2022, expanding at a CAGR of 6.3% from 2016 to 2022.

Browse the full report Irritable Bowel Syndrome with Constipation (IBS-C) Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016–2022 report at http://www.credenceresearch.com/report/irritable-bowel-syndrome-with-constipation-drugs-market

Market Insights

The global IBS-C drugs market is expected to progress at a CAGR of 6.3% during the forecast period. Europe is expected to be the largest regional market for IBS-C drugs followed by North America and Asia Pacific. Gradual growth in physician and patient awareness corresponding to the perpetual growth in disease prevalence are the major growth contributors to the global IBS-C market.

The global IBS-C drugs market is expected to witness significant growth over the forecast period due to significant adoption of IBS drugs. The recent FDA approvals and currently successful clinical trials of IBS drugs will further surge the market.  Growing geriatric population and rise in healthcare expenditure are further creating huge scope for IBS-C drugs market. IBS-C is much prevalent in developed world, where dietary habits, work conditions, and similar such factors contribute to higher risk of lifestyle-related gastrointestinal diseases.

Among the regional markets, Europe is expected to lead the global market in terms of revenue share, expected to reach USD 639 Mn in 2022. Asia Pacific is the most emerging market and is expected to contribute significantly during the forecast period and will undergo progress corresponding to the global trends. The major players in the global IBS-C market include Sucampo AG, Activis, Cardinal Health, Catelent Pharma Solutions, Synergy Pharmaceuticals and others. Rapid commercialization, strong R&D activities, market consolidation strategies brought up by these players will be the major progressive features of the market. Introduction of highly targeted, orally administered peripherally acting mu-opioid receptor antagonist (PAMORA) therapies has also been a key market event.

Drugs such as lubiprostone, methylnaltrexone ad others are widely used for treating IBS-C in North America., thus addressing symptoms such as stomach pain or cramps, bloating, and infrequent or difficult passage of stool. Adoption of these drugs is further higher among elderly population.

Though rare, some probable side effects of these drugs include nausea, further stomach pain, swelling on face, tightness in throat, and others. Majority of IBS-C drugs are widely accepted and the rise in FDA approvals to newer drugs are adding up to create further market opportunities. As a result, several market players are increasingly focusing on research and development activities to come with better and novel pharmaceutical solutions for treating IBS-C.

Lubiprostone to Lead the Global Irritable Bowel Syndrome with Constipation Market at a CAGR of 6.8% during 2016-2022 reviewed on April 4, 2016 by rated 4.9 of 5

Release ID: 1590

About Anurag R

Check Also

roadm-wss-component-market-research-report-now-available-at-research-corridor-300x191

Global Reception Desks in Laminate Market 2016 To 2020 Industry, Size, Share, Growth Prospects, Key Opportunities,Trends and Forecasts: QY Research Reports

The United States Reception Desks in Laminate Industry 2016 Market Research Report is a professional ...